glp-1 overdose Weight loss drugs and addiction: Study shows may help reduce risks 13 Investigates: Family recounts 7-year-old's
Description
New research shows Virta is an effective off-ramp from GLP-1s for sustained weight loss

The future may hold medicines that prevent chronic diseases before they start, aiming for longer, healthier lives rather than just treating illness when it appears

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies
This Lean Cuisine entree is made with no artificial flavors or colors for a satisfying frozen bowl

These two approaches were applied to produce visual representations of body size and shape in Surmount 1 average male and female participants (maximal-tolerated dose group) at baseline and after 72-weeks of tirzepatide treatment
GLP1 drugs like Ozempic and Wegovy are transforming obesity and diabetes care